C. Michael Gibson MD
Proud to be co-author of this New England Journal Med article showing lowering LDL does not always improve outcomes
BackgroundThe cholesteryl ester transfer protein inhibitor evacetrapib substantially raises the high-density lipoprotein (HDL) cholesterol level, reduces the low-density lipoprotein (LDL) cholesterol level, and enhances cellular cholesterol efflux capacity. We sought to determine the effect of evacetrapib on major adverse cardiovascular outcomes in patients with high-risk vascular disease.
ConclusionsAlthough the cholesteryl ester transfer protein inhibitor evacetrapib had favorable effects on established lipid biomarkers, treatment with evacetrapib did not result in a lower rate of cardiovascular events than placebo among patients with high-risk vascular disease.
(Funded by Eli Lilly; ACCELERATE ClinicalTrials.gov number, NCT01687998.)
Read the complete article here.